الثلاثاء 9 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study | King Abdullah International Medical Research Center (KAIMRC) | Rejected | BRENTUXIMAB VEDOTIN | 3 | RJ19/119/J | King Abdulaziz Medical City NG (Riyadh) |
| Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | Janssen-Cilag International NV | Ongoing | Talquetamab | 3 | 80202135EBF3001 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING | Roche | Ongoing | emicizumab | 4 | MO401001 | King Abdulaziz Medical City NG (Jeddah) |
| A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia | Sanofi | Ongoing | iGlarLixi | 4 | OBS17984 | King Fahad Medical City (Riyadh) |
| REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line. | Bayer Saudi Arabia LLC | Ongoing | ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib, | 4 | 22453 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study | King Abdullah International Medical Research Center (KAIMRC) | Rejected | BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine | 2 | RJ19/119/J | King Abdulaziz Medical City NG (Jeddah) |
| A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1 | Cyclo Therapeutics, Inc | Ongoing | Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) | 3 | CTD-TCNPC-301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism | Rezolute Inc | Ongoing | RZ358 | 3 | RZ358-301 | King Abdulaziz Medical City NG (Riyadh) |
| Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial | King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia | Ongoing | Bismuth Subcitrate Potassium , Tetracycline , Metronidazol | 2 | 2231295 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | Roche | Ongoing | Giredestrant , Phesgo | 3 | WO43571 | King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.